The expression of peripheral NK cell-activated receptors (CD94/NKG2C, NKG2D, and CD16) and inhibitory receptors (NKG2A) from BC patients was reduced, highlighting the importance of NK cells as suitable targets for effective antitumor responses in the BC immunosuppressive tumor microenvironment33. The gene discussed is KLRC1; the disease is breast cancer.